Estados financieros detallados de Dermata Therapeutics, Inc. (DRMA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.15, DRMA presenta beneficios negativos (P/E no significativo) y un ROE del -166.67%. La capitalización bursátil es de $1M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1355 | $322 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$1355 | -$322 | 0 | 0 | 0 | 0 | 0 |
| I+D | $2.6M | $1.6M | $3.5M | $5.7M | $4.1M | $8.2M | $2.9M |
| Generales y Administrativos | $1.8M | $1.6M | $4.4M | $4.0M | $4.0M | $4.3M | $4.8M |
| Gastos Operativos | $4.5M | $3.2M | $7.9M | $9.7M | $8.0M | $12.5M | $7.8M |
| Beneficio Operativo | -$4.5M | -$3.2M | -$7.9M | -$9.7M | -$8.0M | -$12.5M | -$7.8M |
| EBITDA | -$4.5M | -$3.0M | -$7.9M | -$9.7M | $247216 | -$12.3M | -$7.8M |
| Gastos por Intereses | $250748 | $197269 | $45613 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$4.7M | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$4.7M | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
| BPA | $-95.50 | $-932.64 | $-152.70 | $-2088.00 | $-401.80 | $-80.32 | $-8.16 |
| BPA Diluido | $-95.50 | $-932.64 | $-152.70 | $-2088.00 | $-399.81 | $-80.32 | $-8.16 |
| Acciones en Circulación (Diluidas) | $3470 | $3470 | $52053 | $4604 | $19496 | $153000 | $926192 |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 |
| Beneficio Operativo | -$1.8M | -$1.9M | -$1.9M | -$3.0M |
| EBITDA | -$1.7M | -$1.9M | -$1.9M | -$3.0M |
| Beneficio Neto | -$1.7M | -$1.9M | -$1.8M | -$3.0M |
| BPA | $-1.65 | $-1.52 | $-0.48 | $-0.74 |
| BPA Diluido | $-1.65 | $-1.52 | $-0.48 | $-0.74 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $2.0M | $530400 | $10.8M | $6.2M | $7.4M | $3.2M | $7.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | $8356 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $2.1M | $605453 | $11.6M | $6.9M | $8.0M | $3.5M | $7.9M |
| Inmovilizado Material | $322 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $2.1M | $605453 | $11.6M | $6.9M | $8.0M | $3.5M | $7.9M |
| Cuentas por Pagar | $337184 | $104276 | $515245 | $496702 | $866028 | $808011 | $460811 |
| Deuda a Corto | $730547 | $3.5M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.7M | $3.8M | $1.5M | $922634 | $1.6M | $2.0M | $1.6M |
| Deuda a Largo | $553191 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $2.3M | $3.8M | $1.5M | $922634 | $1.6M | $2.0M | $1.6M |
| Reservas | -$24.8M | -$28.1M | -$36.0M | -$45.6M | -$53.4M | -$65.7M | -$73.2M |
| Patrimonio Neto | -$210159 | -$3.2M | $10.1M | $6.0M | $6.4M | $1.6M | $6.2M |
| Deuda Total | $1.3M | $3.5M | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | -$708064 | $3.0M | -$10.8M | -$6.2M | -$7.4M | -$3.2M | -$7.5M |
| Capital Circulante | $342710 | -$3.2M | $10.1M | $6.0M | $6.4M | $1.6M | $6.2M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $4.7M | $7.5M | $6.9M | $4.4M |
| Activos Totales | $5.1M | $7.9M | $7.5M | $5.3M |
| Pasivos Totales | $1.1M | $1.6M | $1.1M | $1.8M |
| Patrimonio Neto | $4.0M | $6.2M | $6.4M | $3.5M |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$4.7M | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
| Amortizaciones | $1355 | $322 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | 0 | $1.9M | $930325 | $522082 | $657649 | $143732 |
| Cambio en Capital Circulante | -$74986 | -$755845 | $289551 | -$153576 | $863677 | $466864 | -$342734 |
| Flujo de Caja Operativo | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M |
| Inversiones (CapEx) | 0 | 0 | 0 | $4 | 0 | 0 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | -$40 | -$828 | -$367 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$1.8M | -$1.3M | -$2.5M | -$2.4M |
| Inversiones (CapEx) | 0 | 0 | 0 | -$110667 |
| Flujo de Caja Libre | -$1.8M | -$1.3M | -$2.5M | -$2.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $37841 | $29469 | $43278 | $41780 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | +31.4% | -144.2% | -21.6% | +18.9% | -57.6% | +38.5% |
| Crecimiento BPA (anual) | | -876.6% | +83.6% | -1267.4% | +80.8% | +80.0% | +89.8% |
| Cambio en Acciones (anual) | | +0.0% | +1400.1% | -91.2% | +323.5% | +684.8% | +505.4% |
| Crecimiento FCF (anual) | | -2.7% | -41.3% | -55.2% | +27.5% | -74.2% | +30.5% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-1130.34 | $-1160.96 | $-109.38 | $-1918.80 | $-328.73 | $-72.96 | $-8.38 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $3470 | $3470 | $52053 | $4604 | $19400 | $153000 | $926192 |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -166.67% |
| Rentabilidad sobre capital invertido | -246.61% |
| Rentabilidad sobre activos | -157.28% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 2.81 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -14.56 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -130.43 | -13.36 | -27.35 | -0.47 | -0.23 | -0.17 | -0.28 |
| P/VC | -205.66 | -13.60 | 21.51 | 0.75 | 0.28 | 1.32 | 0.35 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |